EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’

Pablo López Sanz iD, Marta Guzmán Pérez, Claudia Guerrero Ramírez, Silvia Manso Córdoba, María Encarnación Alfaro Martínez, José Manuel Azaña Defez

Clinical and Experimental Dermatology · 2023

DOI: 10.1093/ced/llad160 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Pablo López Sanz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Biosimilar Pharmaceuticals, Mevalonate Kinase Deficiency, Psoriasis. Die Arbeit nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of patients with paradoxical hidradenitis suppurativa receiving biologic therapy should be individualized, but the treatment of these reactions is mainly based on the discontinuation of the culprit drug taking into account the balance between subsequent risks and benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaBiosimilar PharmaceuticalsMevalonate Kinase DeficiencyPsoriasisHumansAdalimumabUstekinumabAntibodies, Monoclonal, Humanized

Substanzen

AdalimumabUstekinumabBiosimilar PharmaceuticalsguselkumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Departments of Dermatology.
  • Internal Medicine, University General Hospital of Albacete, Albacete, Spain.
  • Departments of Dermatology and Internal Medicine, University General Hospital of Albacete, Albacete, Spain.

ORCID-Profile: Pablo López Sanz

Zitieren

APA

López Sanz, P., Guzmán Pérez, M., Guerrero Ramírez, C., Manso Córdoba, S., Alfaro Martínez, M. E., & Azaña Defez, J. M. (2023). Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad160

Vancouver

López Sanz P, Guzmán Pérez M, Guerrero Ramírez C, Manso Córdoba S, Alfaro Martínez ME, Azaña Defez JM. Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad160

BibTeX
@article{LpezSanz2023,
  author = {López Sanz, Pablo and Guzmán Pérez, Marta and Guerrero Ramírez, Claudia and Manso Córdoba, Silvia and Alfaro Martínez, María Encarnación and Azaña Defez, José Manuel},
  title = {Reply to ‘Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on “Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab”’},
  journal = {Clinical and Experimental Dermatology},
  year = {2023},
  doi = {10.1093/ced/llad160}
}
Kostenlos starten →